Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer

Stage IV Renal Cell Cancer Clinical Trial

Official title: Phase Ib/II Trial of Ibrutinib Plus Nivolumab in Patients With Previously-Treated Metastatic Renal Cell Cancer

Status Completed

Clinical Trial Summary

This phase Ib/II trial studies how well ibrutinib and nivolumab work in treating patients with previously-treated kidney cancer that has spread to other parts of the body. Ibrutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread. Giving Ibrutinib and nivolumab may work better in treating patients with metastatic kidney cancer.

Clinical Trial Description

PRIMARY OBJECTIVE:

To assess in a preliminary fashion the feasibility and efficacy of ibrutinib in combination with nivolumab in patients with previously-treated metastatic renal cell cancer (mRCC).

SECONDARY OBJECTIVE:

To evaluate the safety of the combination of ibrutinib and nivolumab in patients with previously treated mRCC. ;

Related Conditions & MeSH terms

• Carcinoma, Renal Cell
• Metastatic Renal Cell Cancer
• Stage IV Renal Cell Cancer

• NCT number: NCT02899078
• Study type: Interventional
• Source: University of California, Davis
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: November 15, 2016
• Completion date: February 24, 2021